MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03406nam a22005057a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
211101s20212021 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0114-5916 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
34533782 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. [Review] |
| 251 ## - Source |
|---|
| Source |
Drug Safety. 44(11):1125-1149, 2021 11. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Drug Saf. 44(11):1125-1149, 2021 11. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
Drug Saf. 2021 Sep 17 |
| 253 ## - Journal Name |
|---|
| Journal name |
Drug safety |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2021 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2022 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
aheadofprint |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
ppublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2021-11-01 |
| 268 ## - Previous citation |
|---|
| -- |
Drug Safety. 2021 Sep 17 |
| 269 ## - Original dates |
|---|
| Original fiscal year |
FY2022 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Drug-induced liver injury (DILI) remains an important, yet challenging diagnosis for physicians. Each year, additional drugs are implicated in DILI and this year was no different, with more than 1400 articles published on the subject. This review examines some of the most significant highlights and controversies in DILI-related research over the past year and their implications for clinical practice. Several new drugs were approved by the US Food and Drug Administration including a number of drugs implicated in causing DILI, particularly among the chemotherapeutic classes. The COVID-19 pandemic was also a major focus of attention in 2020 and we discuss some of the notable aspects of COVID-19-related liver injury and its implications for diagnosing DILI. Updates in diagnostic and causality assessments related to DILI such as the Roussel Uclaf Causality Assessment Method are included, mindful that there is still no single biomarker or diagnostic tool to unequivocally diagnose DILI. Glutamate dehydrogenase received renewed attention as being more specific than alanine aminotransferase. There were a few new reports of previously unrecognized hepatotoxins, including immune modulators and novel gene therapy drugs that we highlight. Updates and new developments of previously described hepatotoxins, such as immune checkpoint inhibitors and anti-tuberculosis drugs are reviewed. Finally, novel technologies such as organoid culture systems to better predict DILI preclinically may be coming of age and determinants of hepatocyte loss, such as calculating PALT are poised to improve our current means of estimating DILI severity and the risk of acute liver failure. Copyright (c) 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Chemical and Drug Induced Liver Injury |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*COVID-19/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Causality |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Risk Factors |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
SARS-CoV-2 |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
United States |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Gastroenterology Fellowship |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Internal Medicine Residency |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
MedStar Georgetown University Hospital |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Aggarwal, Soorya |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Clinton, Joseph |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Davis, William |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Kiparizoska, Sara |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Woo, Stephanie |
| 790 ## - Authors |
|---|
| All authors |
Aggarwal S, Clinton JW, Davis W, Kiparizoska S, Lewis JH, Woo S |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1007/s40264-021-01109-4">https://dx.doi.org/10.1007/s40264-021-01109-4</a> |
| Public note |
https://dx.doi.org/10.1007/s40264-021-01109-4 |
| 858 ## - ORCID |
|---|
| ORCID text |
Clinton, Joseph William |
| Orcid |
<a href="http://orcid.org/0000-0002-9040-4302">http://orcid.org/0000-0002-9040-4302</a> |
| Name |
http://orcid.org/0000-0002-9040-4302 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
